Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BF-200 ALA (Ameluz®) in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT)

NCT05060237 is registered in ClinicalTrials.gov with Biofrontera Bioscience GmbH as lead sponsor.

NCT NCT05060237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05060237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BF-200 ALA (Ameluz®) in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT)
Lead sponsor
Biofrontera Bioscience GmbH
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2021
Completion date
April 20, 2023
Enrollment
112 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis, keratosis, keratosis, actinic